- Home
- AMPY vs CHRS Comparison
AMPY vs CHRS Comparison
Compare AMPY & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMPY
- CHRS
- Stock Information
- Founded
- AMPY 2011
- CHRS 2010
- Country
- AMPY United States
- CHRS United States
- Employees
- AMPY N/A
- CHRS N/A
- Industry
- AMPY Oil & Gas Production
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AMPY Energy
- CHRS Health Care
- Exchange
- AMPY Nasdaq
- CHRS Nasdaq
- Market Cap
- AMPY 118.2M
- CHRS 112.5M
- IPO Year
- AMPY 2011
- CHRS 2014
- Fundamental
- Price
- AMPY $3.25
- CHRS $0.83
- Analyst Decision
- AMPY Strong Buy
- CHRS Buy
- Analyst Count
- AMPY 2
- CHRS 3
- Target Price
- AMPY $10.25
- CHRS $4.68
- AVG Volume (30 Days)
- AMPY 718.0K
- CHRS 1.5M
- Earning Date
- AMPY 05-12-2025
- CHRS 05-12-2025
- Dividend Yield
- AMPY N/A
- CHRS N/A
- EPS Growth
- AMPY N/A
- CHRS N/A
- EPS
- AMPY 0.39
- CHRS N/A
- Revenue
- AMPY $290,431,100.00
- CHRS $272,251,000.00
- Revenue This Year
- AMPY $6.42
- CHRS N/A
- Revenue Next Year
- AMPY $45.85
- CHRS $19.78
- P/E Ratio
- AMPY $8.24
- CHRS $1.95
- Revenue Growth
- AMPY N/A
- CHRS 19.87
- 52 Week Low
- AMPY $2.27
- CHRS $0.66
- 52 Week High
- AMPY $8.15
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- AMPY 61.93
- CHRS 48.25
- Support Level
- AMPY $3.18
- CHRS $0.74
- Resistance Level
- AMPY $3.46
- CHRS $0.82
- Average True Range (ATR)
- AMPY 0.17
- CHRS 0.05
- MACD
- AMPY 0.07
- CHRS 0.01
- Stochastic Oscillator
- AMPY 75.58
- CHRS 90.48
About AMPY Amplify Energy Corp.
Amplify Energy Corp is an independent oil and natural gas company engaged in the acquisition, development, exploitation, and production of oil and natural gas properties in the United States. The company's oil and natural gas properties are located in large, mature oil and natural gas reservoirs. The company assets consists of producing oil and natural gas properties located in Oklahoma, the Rockies, federal waters offshore Southern California, East Texas/North Louisiana and Eagle Ford.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.